A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

To join this study, you generally need to be an adult (18 years or older) with Diffuse Large B-Cell Lymphoma (DLBCL) that has returned or hasn't responded to previous treatments. Your doctors must have confirmed that your specific type of lymphoma is called CD20+ DLBCL.

You would have already received at least one course of cancer treatment that included a medicine like rituximab. You'd also need to be in reasonably good health overall, with a life expectancy of more than three months. The study is specifically for those who either haven't benefited from, or can't have, certain other advanced treatments like a stem cell transplant or CAR T-cell therapy.

However, you wouldn't be able to join if your lymphoma is in your brain or spinal cord, or if you've already had certain drugs that are similar to the ones being tested in this study (like highly specific CD3 and CD20 targeting drugs, or the full R-GemOx treatment). They also need to be able to measure your cancer, so they can track if the treatment is working.

If you decide to take part, you'll be randomly assigned to one of three treatment groups. Two groups will receive epcoritamab, given as injections under the skin, for up to 12 cycles. One of these groups will also take lenalidomide tablets. The third group will receive rituximab, gemcitabine, and oxaliplatin, given through a drip into a vein, for up to 4 cycles. Each cycle of treatment lasts for 28 days.

Taking part means you will have regular visits to the hospital or clinic. These visits will involve various medical checks, including blood tests, physical exams, and discussions about any side effects you might be experiencing. You'll also be asked to fill out questionnaires about how you're feeling. The medical team will closely monitor your condition and how your cancer is responding to the treatment throughout the study. This will likely involve more hospital visits and tests than you might expect with standard care, and the total duration of your active participation could be several months, depending on your assigned treatment arm.